Evrysdi® (risdiplam) Receives CADTH Reimbursement Recommendation for Some Patients with Spinal Muscular Atrophy newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
/CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has issued an Interim Order authorization for casirivimab and imdevimab.
Ontario urged to hold lottery for key drug used on COVID-19 patients Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Nathan Denette/The Canadian Press
Ontario should set up a lottery to allocate one of the few medications known to reduce mortality in critically ill COVID-19 patients in case supplies are exhausted during the punishing third wave, according to a new paper from the province’s scientific advisers.
The Ontario COVID-19 Science Advisory Table is asking the provincial government to prepare for the day hospitals run out of tocilizumab, an anti-inflammatory drug that physicians are already administering in smaller doses to make limited amounts go further.
iii
MISSISSAUGA, ON, April 15, 2021 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has granted EVRYSDI
Ⓡ (risdiplam) market authorization for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.
iii
EVRYSDI works by helping the body make more of a protein called, SMN protein. EVRYSDI increases and sustains the amount of SMN protein in the body, which helps to treat SMA. It is the first medicine for SMA that can be taken at home and is administered once daily by mouth or feeding tube.
iii The Health Canada approval of EVRYSDI is a welcome addition in our ability to treat SMA. It is an efficacious treatment that significantly increases survival motor neuron (SMN) protein in SMA patients, said Dr. Hugh McMillan, Pediatric Neurologist at the Children s Hospital of Eastern Ontario. We now have an additional and convenient treatment option with EVRYSDI, as it s the first at-home and oral option for patients
Hospitals running out of key drug for COVID-19 patients Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Frank Gunn/The Canadian Press
Ontario physicians have been urged to ration one of only two drugs known to reduce mortality in critically ill COVID-19 patients, a harbinger of what lies ahead for other provinces if the third wave keeps rising and Canada cannot secure more of the medication.
A shortage of the anti-inflammatory drug tocilizumab is just one of the challenges Canadian hospitals face as faster-spreading and more dangerous variants overtake older versions of the coronavirus. British Columbia, Saskatchewan, New Brunswick and Ontario all have more COVID-19 patients in their intensive care units than at any other time during the pandemic.